- Home
- PII vs RNA Comparison
PII vs RNA Comparison
Compare PII & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PII
- RNA
- Stock Information
- Founded
- PII 1954
- RNA 2012
- Country
- PII United States
- RNA United States
- Employees
- PII N/A
- RNA N/A
- Industry
- PII Recreational Games/Products/Toys
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- PII Consumer Discretionary
- RNA Health Care
- Exchange
- PII Nasdaq
- RNA Nasdaq
- Market Cap
- PII 3.7B
- RNA 4.0B
- IPO Year
- PII 1987
- RNA 2020
- Fundamental
- Price
- PII $66.84
- RNA $71.69
- Analyst Decision
- PII Hold
- RNA Buy
- Analyst Count
- PII 11
- RNA 20
- Target Price
- PII $52.80
- RNA $69.26
- AVG Volume (30 Days)
- PII 834.4K
- RNA 4.3M
- Earning Date
- PII 10-28-2025
- RNA 11-10-2025
- Dividend Yield
- PII 4.04%
- RNA N/A
- EPS Growth
- PII N/A
- RNA N/A
- EPS
- PII N/A
- RNA N/A
- Revenue
- PII $7,076,200,000.00
- RNA $20,868,000.00
- Revenue This Year
- PII N/A
- RNA N/A
- Revenue Next Year
- PII $1.02
- RNA $108.97
- P/E Ratio
- PII N/A
- RNA N/A
- Revenue Growth
- PII N/A
- RNA 106.27
- 52 Week Low
- PII $30.92
- RNA $21.51
- 52 Week High
- PII $75.25
- RNA $71.78
- Technical
- Relative Strength Index (RSI)
- PII 56.22
- RNA 80.21
- Support Level
- PII $59.63
- RNA $70.42
- Resistance Level
- PII $67.80
- RNA $71.04
- Average True Range (ATR)
- PII 2.38
- RNA 0.46
- MACD
- PII 0.19
- RNA -0.75
- Stochastic Oscillator
- PII 87.38
- RNA 96.77
About PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.